Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more
Ind-Swift Laboratories Limited (INDSWFTLAB) - Net Assets
Latest net assets as of September 2025: ₹13.07 Billion INR
Based on the latest financial reports, Ind-Swift Laboratories Limited (INDSWFTLAB) has net assets worth ₹13.07 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹15.44 Billion) and total liabilities (₹2.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹13.07 Billion |
| % of Total Assets | 84.66% |
| Annual Growth Rate | 9.98% |
| 5-Year Change | 94.39% |
| 10-Year Change | 126.69% |
| Growth Volatility | 20.25 |
Ind-Swift Laboratories Limited - Net Assets Trend (2006–2025)
This chart illustrates how Ind-Swift Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ind-Swift Laboratories Limited (2006–2025)
The table below shows the annual net assets of Ind-Swift Laboratories Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹11.73 Billion | +44.44% |
| 2024-03-31 | ₹8.12 Billion | +19.08% |
| 2023-03-31 | ₹6.82 Billion | +13.49% |
| 2022-03-31 | ₹6.01 Billion | -0.42% |
| 2021-03-31 | ₹6.03 Billion | -5.81% |
| 2020-03-31 | ₹6.41 Billion | +8.99% |
| 2019-03-31 | ₹5.88 Billion | +6.25% |
| 2018-03-31 | ₹5.53 Billion | +4.13% |
| 2017-03-31 | ₹5.31 Billion | +2.69% |
| 2016-03-31 | ₹5.17 Billion | -12.97% |
| 2015-03-31 | ₹5.95 Billion | -18.02% |
| 2014-03-31 | ₹7.25 Billion | -15.02% |
| 2013-03-31 | ₹8.53 Billion | +5.15% |
| 2012-03-31 | ₹8.12 Billion | +39.10% |
| 2011-03-31 | ₹5.84 Billion | +30.17% |
| 2010-03-31 | ₹4.48 Billion | +23.46% |
| 2009-03-31 | ₹3.63 Billion | +8.90% |
| 2008-03-31 | ₹3.33 Billion | +7.05% |
| 2007-03-31 | ₹3.11 Billion | +61.96% |
| 2006-03-31 | ₹1.92 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ind-Swift Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 137538500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹687.44 Million | 5.86% |
| Other Components | ₹12.42 Billion | 105.86% |
| Total Equity | ₹11.73 Billion | 100.00% |
Ind-Swift Laboratories Limited Competitors by Market Cap
The table below lists competitors of Ind-Swift Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Turnkey Communication Services PCL
BK:TKC
|
$41.73 Million |
|
SYGNITY S.A. ZY 1
F:CPN
|
$41.74 Million |
|
MNC Vision Networks PT
JK:IPTV
|
$41.76 Million |
|
Embellence Group AB
ST:EMBELL
|
$41.76 Million |
|
Origin Property PCL
BK:ORI
|
$41.73 Million |
|
RLAIF
OTCQB:RLAIF
|
$41.73 Million |
|
Propdo Ltd
TA:PRPD
|
$41.73 Million |
|
Diamond Building Products Public Company Limited
BK:DRT
|
$41.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ind-Swift Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,361,773,000 to 11,729,997,000, a change of 2,368,224,000 (25.3%).
- Net income of 2,504,766,000 contributed positively to equity growth.
- Share repurchases of 926,341,000 reduced equity.
- New share issuances of 926,341,000 increased equity.
- Other comprehensive income decreased equity by 1,781,325,000.
- Other factors increased equity by 1,644,783,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹2.50 Billion | +21.35% |
| Share Repurchases | ₹926.34 Million | -7.9% |
| Share Issuances | ₹926.34 Million | +7.9% |
| Other Comprehensive Income | ₹-1.78 Billion | -15.19% |
| Other Changes | ₹1.64 Billion | +14.02% |
| Total Change | ₹- | 25.30% |
Book Value vs Market Value Analysis
This analysis compares Ind-Swift Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.73x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.55x to 0.73x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹94.11 | ₹145.87 | x |
| 2007-03-31 | ₹138.71 | ₹145.87 | x |
| 2008-03-31 | ₹142.55 | ₹145.87 | x |
| 2009-03-31 | ₹137.63 | ₹145.87 | x |
| 2010-03-31 | ₹160.53 | ₹145.87 | x |
| 2011-03-31 | ₹181.90 | ₹145.87 | x |
| 2012-03-31 | ₹221.52 | ₹145.87 | x |
| 2013-03-31 | ₹215.88 | ₹145.87 | x |
| 2014-03-31 | ₹177.05 | ₹145.87 | x |
| 2015-03-31 | ₹147.96 | ₹145.87 | x |
| 2016-03-31 | ₹126.31 | ₹145.87 | x |
| 2017-03-31 | ₹124.86 | ₹145.87 | x |
| 2018-03-31 | ₹122.76 | ₹145.87 | x |
| 2019-03-31 | ₹110.54 | ₹145.87 | x |
| 2020-03-31 | ₹129.52 | ₹145.87 | x |
| 2021-03-31 | ₹102.14 | ₹145.87 | x |
| 2022-03-31 | ₹101.71 | ₹145.87 | x |
| 2023-03-31 | ₹115.41 | ₹145.87 | x |
| 2024-03-31 | ₹158.43 | ₹145.87 | x |
| 2025-03-31 | ₹198.52 | ₹145.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ind-Swift Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.35%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 44.59%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.23x
- Recent ROE (21.35%) is above the historical average (4.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 17.42% | 10.65% | 0.61x | 2.67x | ₹142.64 Million |
| 2007 | 5.86% | 5.21% | 0.50x | 2.24x | ₹-129.07 Million |
| 2008 | 9.42% | 6.86% | 0.57x | 2.42x | ₹-19.21 Million |
| 2009 | 11.12% | 6.84% | 0.61x | 2.64x | ₹40.82 Million |
| 2010 | 12.58% | 7.18% | 0.62x | 2.84x | ₹115.59 Million |
| 2011 | 15.48% | 8.53% | 0.60x | 3.01x | ₹316.51 Million |
| 2012 | 10.82% | 6.33% | 0.64x | 2.68x | ₹67.86 Million |
| 2013 | -13.81% | -10.38% | 0.48x | 2.78x | ₹-2.03 Billion |
| 2014 | -16.82% | -12.64% | 0.42x | 3.20x | ₹-1.95 Billion |
| 2015 | -19.69% | -18.07% | 0.29x | 3.70x | ₹-1.80 Billion |
| 2016 | -11.34% | -8.98% | 0.29x | 4.29x | ₹-1.10 Billion |
| 2017 | -7.37% | -5.61% | 0.33x | 4.02x | ₹-922.67 Million |
| 2018 | 3.97% | 2.87% | 0.38x | 3.66x | ₹-333.48 Million |
| 2019 | 4.79% | 3.83% | 0.39x | 3.19x | ₹-314.47 Million |
| 2020 | -3.31% | -2.72% | 0.42x | 2.92x | ₹-852.52 Million |
| 2021 | -0.52% | -0.35% | 0.49x | 3.01x | ₹-634.98 Million |
| 2022 | -0.36% | -0.21% | 0.58x | 3.00x | ₹-622.46 Million |
| 2023 | 6.98% | 3.94% | 0.66x | 2.67x | ₹-205.96 Million |
| 2024 | 44.97% | 32.86% | 0.88x | 1.56x | ₹3.27 Billion |
| 2025 | 21.35% | 44.59% | 0.39x | 1.23x | ₹1.33 Billion |
Industry Comparison
This section compares Ind-Swift Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ind-Swift Laboratories Limited (INDSWFTLAB) | ₹13.07 Billion | 17.42% | 0.18x | $41.73 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |